Cereno Scientific targets Q4 2028 topline data for Phase IIb EPIMODE trial in pulmonary arterial hypertension

• Cereno Scientific flagged delays to first patient randomization in its Phase IIb EPIMODE trial of CS1 in pulmonary arterial hypertension.
• Topline results have not been presented yet; the readout remains scheduled for Q4 2028.
• Management still expects recruitment to finish in 2027, keeping the broader development timeline intact despite start-up setbacks.
• Site expansion remains the key execution driver, with up to 15 sites planned to be activated by year-end 2026.
• The trial aims to assess CS1’s potential clinical benefit and risk profile as an add-on therapy, supporting dose selection for later-stage development.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cereno Scientific AB published the original content used to generate this news brief on October 08, 2026, and is solely responsible for the information contained therein.